EVMN peer analysis
Evommune (EVMN) against its competitors: price, today's move, 1-year return and market value side by side.
EVMN and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ARTV Artiva Biotherapeutics | $4.08 | 0.37% | 17.20% | $198.25M |
| CDXS Codexis | $1.00 | -9.91% | -34.32% | $121.55M |
| CLYM Climb Bio | $12.23 | 4.17% | 540.98% | $673.73M |
| EYPT EyePoint | $0.36 | -10.76% | -96.41% | $33.76M |
| FTRE Fortrea | $20.38 | -4.75% | 90.04% | $2.02B |
| KPTI Karyopharm Therapeutics | $0.02 | -56.50% | -99.68% | $369.71K |
| LGND Ligand Pharmaceuticals | $317.40 | 1.03% | 55.25% | $6.29B |
| OABI OmniAb | $5.10 | 0.00% | 269.93% | $744.62M |
| ZYME Zymeworks | $28.92 | -8.07% | 91.07% | $2.26B |
| EVMN Evommune | $8.64 | 10.20% | -57.31% | $285.26M |
- EVMN's peers: ARTV (Artiva Biotherapeutics), CDXS (Codexis), CLYM (Climb Bio), EYPT (EyePoint), FTRE (Fortrea), KPTI (Karyopharm Therapeutics), LGND (Ligand Pharmaceuticals), OABI (OmniAb).
Updated 2026-11-12 02:51 UTC